Adalimumab for the treatment of pediatric Crohn’s disease

References

• Auvin S, Molinie F, Gower-Rousseau C, et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988–1999). J Pediatr Gastroenterol Nutr 2005;41:49-55
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39
   PubMed Web of Science ®Google Scholar
• Malaty HM, Fan X, Opekun AR, et al. Rising incidence of inflammatory bowel disease among children: a 12-year study. J Pediatr Gastroenterol Nutr 2010;50:27-31
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114-22
   PubMed Web of Science ®Google Scholar
• Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease: a systematic review. J Clin Gastroenterol 2012;46:581-9
   PubMed Web of Science ®Google Scholar
• Aloi M, Lionetti P, Barabino A, et al. SIGENP IBD Group. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis 2014;20:597-605
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014;8:1179-207
   PubMed Web of Science ®Google Scholar
• De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis 2013;19:429-44
   PubMed Web of Science ®Google Scholar
• Osterman M.T. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol 2013;47:212-21
   PubMed Web of Science ®Google Scholar
• Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013;15:315
   PubMedGoogle Scholar
• Sandborn WJ. The future of inflammatory bowel disease therapy: where do we go from here? Dig Dis 2012;30:140-4
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohn’s Colitis 2010;4:63-101
   Google Scholar
• Hanauer SB. Medical management of Crohn’s disease: treatment algorithms 2009. Dig Dis 2009;27:536-41
   PubMed Web of Science ®Google Scholar
• Remicade approved for children with Crohn’s disease. FDA Consum 2006;40:6
   Google Scholar
• Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132:863-73
   PubMed Web of Science ®Google Scholar
• Hyams J, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology 2012;143:365-74
   PubMed Web of Science ®Google Scholar
• Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension. Curr Med Res Opin 2011;27:651-62
   PubMed Web of Science ®Google Scholar
• De Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of Infliximab maintenance treatment in pediatric Crohn’s disease is limited. Alimentary Pharmacol Ther 2011;33:243-50
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Griffiths A, et al. Long-term Outcome of Maintenance Infliximab Therapy in Children with Crohn’s Disease. Inflamm Bowel Dis 2009;15:816-22
   PubMed Web of Science ®Google Scholar
• Crombè V, Salleron J, Savoye G, et al. Long-term Outcome of Treatment with Infliximab in Pediatric-onset Crohn’s Disease: A Population-Based Study. Inflamm Bowel Dis 2011;17:2144-52
   PubMed Web of Science ®Google Scholar
• Assa A, Hartman C, Weiss B, et al. Long-term Outcome of Tumor Necrosis Factor alpha Antagonist’s Treatment in Pediatric Crohn’s disease. J Crohns Colitis 2013;7:369-76
   PubMed Web of Science ®Google Scholar
• Nuti F, Viola F, Civitelli F, et al. Biological therapy in a pediatric Crohn’s disease population at a referral center. J Pediatr Gastroenterol Nutr 2014;58:582-7
   PubMed Web of Science ®Google Scholar
• Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1683-7
   PubMed Web of Science ®Google Scholar
• Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn’s disease. Am J Gastroenterol 2009;104:2566-71
   PubMed Web of Science ®Google Scholar
• Rosh JR, Lerer T, Markowitz J, et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn’s disease. Am J Gastroenterol 2009;104:3042-9
   PubMed Web of Science ®Google Scholar
• Russell RK, Wilson ML, Loganathan S, et al. A British Society of Pediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:946-53
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660-7
   PubMed Web of Science ®Google Scholar
• Kim MJ, Lee JS, Lee JH, et al. Infliximab therapy in children with Crohn’s disease: a one-year evaluation of efficacy comparing ‘top-down’ and ‘step-up’ strategies. Acta Paediatr 2011;100:451-5
   PubMed Web of Science ®Google Scholar
• Lee JS, Lee JH, Lee JH, et al. Efficacy of early treatment with infliximab in pediatric Crohn’s disease. World J Gastroenterol 2010;16:1776-81
   PubMed Web of Science ®Google Scholar
• Lee YM, Kang B, Lee Y, et al. Infliximab ‘Top-Down’ Strategy is Superior to ‘Step-Up’ in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn’s Disease. J Pediatr Gastroenterol Nutr 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wyneski MJ, Green A, Kay M, et al. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2008;47:19-25
   PubMed Web of Science ®Google Scholar
• Rosenbach Y, Hartman C, Shapiro R, et al. Adalimumab treatment in children with refractory Crohn’s disease. Dig Dis Sci 2010;55:747-53
   PubMed Web of Science ®Google Scholar
• Martin-de-Carpi J, Pociello N, Varea V. Long-term efficacy of adalimumab in pediatric Crohn’s disease patients naive to other anti-TNF therapies. J Crohns Colitis 2010;4:594-8
   PubMed Web of Science ®Google Scholar
• Cameron FL, Wilson ML, Basheer N, et al. Anti-TNF therapy for pediatric IBD: the Scottish national experience. Arch Dis Child 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Cozijnsen M, Duif V, Kokke F, et al. Dutch PIBD Working Group Kids with Crohn and Colitis. Adalimumab therapy in children with Crohn disease previously treated with infliximab. J Pediatr Gastroenterol Nutr 2015;60:205-10
   PubMed Web of Science ®Google Scholar
• Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14:839-49
   PubMed Web of Science ®Google Scholar
• Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn’s disease. Nat Rev Gastroenterol Hepatol 2009;6:513-23
   PubMed Web of Science ®Google Scholar
• Kierkuś J, Iwańczak B, Wegner A, et al. Monotherapy With Infliximab vs. Combo Therapy in the Maintenance of Clinical Remission in Children With Moderate to Severe Crohn’s Disease - a Randomized Study. J Pediatr Gastroenterol Nutr 2015; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Sharma S, Eckert D, Hyams JS, et al. Pharmacokinetics and Exposure-Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohn’s Disease: Results from a Randomized, Multicenter, Phase-3 Study. Inflamm Bowel Dis 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gouldthorpe O, Catto-Smith AG, Alex G, et al. Loss of response to long-term infliximab therapy in children with Crohn’s disease. Pharmaceuticals 2013;6:1322-34
   Google Scholar
• Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2014;20:606-13
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Ardizzone S, Bianchi Porro G. Adalimumab for the treatment of Crohn’s disease. Biologics 2008;2:763-77
   PubMedGoogle Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the Classic II trial. Gut 2007;56:1232-9
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Inflamm Bowel Dis 2009;15:1264-75
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000;95:3189-94
   PubMed Web of Science ®Google Scholar
• Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in pediatric Crohn’s disease. Aliment Pharmacol Ther 2003;18:425-31
   PubMed Web of Science ®Google Scholar
• Walters TD, Kim MO, Denson LA, et al. PRO-KIIDS Research Group. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease. Gastroenterology 2014;146:383-91
   PubMed Web of Science ®Google Scholar
• Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative Disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
   PubMed Web of Science ®Google Scholar
• Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn’s Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis 2011;17:758-66
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma (HSTCL) associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7
   PubMed Web of Science ®Google Scholar
• Cucchiara S, Escher JC, Hildebrand H, et al. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 2009;48:257-67
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41
   PubMed Web of Science ®Google Scholar
• Dulai PS, Thompson KD, Blunt HB, et al. Risks of Serious Infection or Lymphoma With Anti-Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review. Clin Gastroenterol Hepatol 2014;12:1443-51
   PubMed Web of Science ®Google Scholar
• Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010;8:268-74
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8
   PubMed Web of Science ®Google Scholar
• Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of non-melanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011;141:1612-20
   PubMed Web of Science ®Google Scholar
• Long MD, Martin C, Pipkin CA, et al. Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-9
   PubMed Web of Science ®Google Scholar
• Colletti RB, Cucchiara S, Dubinsky M, et al. Malignancies in Children Receiving Infliximab and Other Inflammatory Bowel Disease Therapies: An Inflammatory Bowel Disease Multicenter, Prospective, Long-Term Registry of Pediatric Patients (Develop) Registry Data. Gastroenterology 2013;144(Suppl 1):147
   Google Scholar
• Afif W, Loftus EVJr. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am 2010;94:115-33
   PubMed Web of Science ®Google Scholar
• De Greef E, Vandenplas Y, Veereman-Wauters G. Opportunistic infections in pediatric inflammatory bowel disease patients. Arch Dis Child 2012;97:5-7
   PubMed Web of Science ®Google Scholar
• Rahier JF. Prevention and management of infectious complications in IBD. Dig Dis 2012;30:408-14
   PubMed Web of Science ®Google Scholar
• Dave M, Purohit T, Razonable R, Loftus EVJr. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis 2014;20:196-212
   PubMed Web of Science ®Google Scholar
• Fasci Spurio F, Aratari A, Margagnoni G, et al. Early treatment in Crohn’s disease: do we have enough evidence to reverse the therapeutic pyramid? J Gastrointestin Liver Dis 2012;21:67-73
   PubMed Web of Science ®Google Scholar
• Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis 2012;30(Suppl 3):67-72
   PubMed Web of Science ®Google Scholar
• Romberg-Camps MJ, Dagnelie PC, Kester AD, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009;104:371-83
   PubMed Web of Science ®Google Scholar
• Laharie D, Salzmann M, Boubekeur H, et al. Predictors of response to infliximab in luminal Crohn’s disease. Gastroenterol Clin Biol 2005;29:145-9
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology 2006;130:650-6
   PubMed Web of Science ®Google Scholar
• Savoye G, Salleron J, Gower-Rousseau C, et al. Clinical Predictors at Diagnosis of Disabling Pediatric Crohn’s Disease. Inflamm Bowel Dis 2012;18:2072-8
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel Dis 2009;15:1308-19
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 2013;72:517-24
   PubMed Web of Science ®Google Scholar